LY-411575, also known as LY411575, is a small molecule inhibitor of gamma-secretase, an enzyme that cleaves the amyloid precursor protein (APP) to produce beta-amyloid peptides. It was first developed by Eli Lilly and Company for the treatment of Alzheimer's disease.
Chemical name:
The chemical name of LY-411575 is (2S)-2-(3,5-difluorophenyl)-N-(2-methylpropyl)-4-(2-oxo-1,3-oxazolidin-5-yl)-N'-(3-morpholin-4-ylpropyl)butanediamide.
Molecular formula:
The molecular formula of LY-411575 is C23H32F2N4O3.
Formula weight:
The formula weight of LY-411575 is 458.53 g/mol.
CAS No:
The CAS number of LY-411575 is 209984-57-6.
Top ten keywords from Google and Synonyms:
Synonyms: LY411, LY-411, LY411575, N-[2-(Dimethylamino)ethyl]-N-(3,5-difluorophenyl)-2-[(5-methyl-3-oxo-2-oxazolidinyl)methyl]benzamide
Health benefits:
LY-411575 has been primarily used for the treatment of Alzheimer's disease, a neurodegenerative disorder characterized by the accumulation of beta-amyloid peptides in the brain. By inhibiting the activity of gamma-secretase, LY-411575 can potentially reduce the production of beta-amyloid peptides and prevent their aggregation into toxic plaques in the brain.
Potential effects:
LY-411575 works by inhibiting the activity of gamma-secretase, an enzyme that cleaves the amyloid precursor protein (APP) to produce beta-amyloid peptides. By reducing the production of beta-amyloid peptides, LY-411575 can potentially slow down the progression of Alzheimer's disease and improve cognitive function in affected individuals.
Product mechanism:
LY-411575 is a potent and selective inhibitor of gamma-secretase, an enzyme that plays a critical role in the production of beta-amyloid peptides in the brain. By binding to the active site of gamma-secretase, LY-411575 prevents the enzyme from cleaving APP and producing beta-amyloid peptides. This inhibition of gamma-secretase activity can help to reduce the production of beta-amyloid peptides and prevent their aggregation into toxic plaques in the brain.
Safety:
Like any medication, LY-411575 may have some potential side effects. However, most reported side effects of LY-411575 are mild to moderate in severity and manageable. Common side effects include headache, nausea, and diarrhea. In rare cases, severe adverse reactions such as liver damage, bleeding, and infections may occur. Therefore, it is important to discuss the risks and benefits of LY-411575 with your doctor before taking it.
Dosing information:
The recommended dosage of LY-411575 for the treatment of Alzheimer's disease is 20-60 mg per day. The medication should be taken orally with or without food. Patients should be monitored for any signs of side effects, and the dosage may be adjusted based on their individual response to the medication.
Conclusion:
In conclusion, LY-411575 is a promising medication for the treatment of Alzheimer's disease that works by inhibiting the activity of gamma-secretase. It helps to reduce the production of beta-amyloid peptides and prevent their aggregation into toxic plaques in the brain. Although LY-411575 has shown potential benefits in clinical trials, more studies are needed to establish its long-term safety and efficacy. Therefore, patients should always consult with their healthcare provider before starting any new medication
